Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers
•Anti-SP antibody titer compared after second and third doses of the BNT162b2 vaccine.•Study conducted on healthcare workers directly exposed to COVID-19 patients.•Anti-SP IgG titer decreased slowly after second dose of the vaccine.•Peak IgG titer 4.1-fold higher after the third dose than after firs...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2023-01, Vol.41 (2), p.365-371 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 371 |
|---|---|
| container_issue | 2 |
| container_start_page | 365 |
| container_title | Vaccine |
| container_volume | 41 |
| creator | Tanaka, Hidenori Mukai, Junji Kushibiki, Kenichi Mizushima, Sayuri Maeda, Kyoko Fujimoto, Yuko Sawada, Ryugo Oda, Manabu Okuda, Hiroshi Yamaki, Mayumi Hashiguchi, Shin Kawai, Ichiro Kawaguchi, Izumi Masuda, Noriyuki Matsushita, Haruhiko |
| description | •Anti-SP antibody titer compared after second and third doses of the BNT162b2 vaccine.•Study conducted on healthcare workers directly exposed to COVID-19 patients.•Anti-SP IgG titer decreased slowly after second dose of the vaccine.•Peak IgG titer 4.1-fold higher after the third dose than after first and second doses.•Adverse events following immunization were generally mild to moderate.
Administration of three doses of Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine was completed in Japan in the spring of 2022. This study aimed to evaluate the antibody responses, and kinetics of three doses of vaccine in healthcare workers (HCWs).
We conducted a longitudinal cohort study with HCWs, who had no history of COVID-19 or serologic evidence of SARS-CoV-2 infection, from a single hospital. Immunoglobulin G (IgG) titers of anti-SARS-CoV-2 spike protein (SP) and nucleocapsid protein (NP) titers were measured using an automated chemiluminescent enzyme immunoassay system.
A total of 636 HCWs participated in the study. The anti-SP IgG titers decreased slowly after the second dose of the BNT162b2 vaccine in all participants, and robust antibody response was observed after the third dose of the vaccine. The peak anti-SP IgG titer after the third dose was approximately 4.1-fold higher than that after the first and second doses, and the rate of decrease in the anti-SP IgG titer after the third dose was significantly more gradual, than that after the second dose. After the second dose of vaccine, the antibody response was weaker in older participants than in younger participants, and in males than in females respectively, whereas the response to the third dose of vaccine did not differ significantly by sex or age. Adverse events following immunization were generally mild to moderate.
The third dose of the BNT162b2 vaccine induced a significant and sustained increase in anti-SP IgG titers, and was generally safe and well-tolerated. |
| doi_str_mv | 10.1016/j.vaccine.2022.11.049 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2746388377</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X22014621</els_id><sourcerecordid>2746388377</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-7f5d64a11ba3d7c766828961cea3fa9b535232de44d772516c83485e24f2e6c3</originalsourceid><addsrcrecordid>eNqFkU1vEzEQQC0EoqHwE0CWuHDx1l9r755QCIVWqlqpjSpulteeVRw262JvgvrvcUjaAxcOlj3Wmxl7HkLvGa0YZepsXe2sc2GEilPOK8YqKtsXaMYaLQivWfMSzShXkkhGf5ygNzmvKaW1YO1rdCKUVOUsZiif9z24CcceTysoKySPfcywv_lyvWSKdxwvbu4vvxLW4s3t9RwfG-M4YjtOgdzNb-_IIt4T_jfuon_EA-xgyDiMeAV2mFbOJsC_Y_oJKb9Fr3o7ZHh33E_R8tv5cnFBrm6-Xy7mV8RJSSei-9oraRnrrPDaaaUa3rSKObCit21Xi5oL7kFKr3X5sXKNkE0NXPYclBOn6NOh7EOKv7aQJ7MJ2cEw2BHiNhuupRJNI7Qu6Md_0HXcprE8rlB1qykXbV2o-kC5FHNO0JuHFDY2PRpGzV6KWZvjbMxeimHMFCkl78Ox-rbbgH_OerJQgM8HoIwMdgGSyS7A6MCHVOQYH8N_WvwBs6CcLg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2759702395</pqid></control><display><type>article</type><title>Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Tanaka, Hidenori ; Mukai, Junji ; Kushibiki, Kenichi ; Mizushima, Sayuri ; Maeda, Kyoko ; Fujimoto, Yuko ; Sawada, Ryugo ; Oda, Manabu ; Okuda, Hiroshi ; Yamaki, Mayumi ; Hashiguchi, Shin ; Kawai, Ichiro ; Kawaguchi, Izumi ; Masuda, Noriyuki ; Matsushita, Haruhiko</creator><creatorcontrib>Tanaka, Hidenori ; Mukai, Junji ; Kushibiki, Kenichi ; Mizushima, Sayuri ; Maeda, Kyoko ; Fujimoto, Yuko ; Sawada, Ryugo ; Oda, Manabu ; Okuda, Hiroshi ; Yamaki, Mayumi ; Hashiguchi, Shin ; Kawai, Ichiro ; Kawaguchi, Izumi ; Masuda, Noriyuki ; Matsushita, Haruhiko</creatorcontrib><description>•Anti-SP antibody titer compared after second and third doses of the BNT162b2 vaccine.•Study conducted on healthcare workers directly exposed to COVID-19 patients.•Anti-SP IgG titer decreased slowly after second dose of the vaccine.•Peak IgG titer 4.1-fold higher after the third dose than after first and second doses.•Adverse events following immunization were generally mild to moderate.
Administration of three doses of Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine was completed in Japan in the spring of 2022. This study aimed to evaluate the antibody responses, and kinetics of three doses of vaccine in healthcare workers (HCWs).
We conducted a longitudinal cohort study with HCWs, who had no history of COVID-19 or serologic evidence of SARS-CoV-2 infection, from a single hospital. Immunoglobulin G (IgG) titers of anti-SARS-CoV-2 spike protein (SP) and nucleocapsid protein (NP) titers were measured using an automated chemiluminescent enzyme immunoassay system.
A total of 636 HCWs participated in the study. The anti-SP IgG titers decreased slowly after the second dose of the BNT162b2 vaccine in all participants, and robust antibody response was observed after the third dose of the vaccine. The peak anti-SP IgG titer after the third dose was approximately 4.1-fold higher than that after the first and second doses, and the rate of decrease in the anti-SP IgG titer after the third dose was significantly more gradual, than that after the second dose. After the second dose of vaccine, the antibody response was weaker in older participants than in younger participants, and in males than in females respectively, whereas the response to the third dose of vaccine did not differ significantly by sex or age. Adverse events following immunization were generally mild to moderate.
The third dose of the BNT162b2 vaccine induced a significant and sustained increase in anti-SP IgG titers, and was generally safe and well-tolerated.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2022.11.049</identifier><identifier>PMID: 36460533</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Aged ; Antibodies ; Antibodies, Viral ; Antibody Formation ; Antibody response ; BNT162 Vaccine ; BNT162b2 vaccine ; Booster vaccination ; Chemiluminescence ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Enzyme immunoassay ; Female ; Health care ; Health Personnel ; Healthcare workers ; Humans ; IgG antibody ; Immunization ; Immunoassay ; Immunoglobulin G ; Longitudinal Studies ; Male ; Males ; Medical personnel ; mRNA ; mRNA Vaccines ; Nucleocapsids ; Pandemics ; Proteins ; Questionnaires ; SARS-CoV-2 ; SARS-CoV-2 spike protein ; Severe acute respiratory syndrome coronavirus 2 ; Sex differences ; Spike protein ; Vaccines ; Values</subject><ispartof>Vaccine, 2023-01, Vol.41 (2), p.365-371</ispartof><rights>2022</rights><rights>Copyright © 2022. Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited Jan 9, 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-7f5d64a11ba3d7c766828961cea3fa9b535232de44d772516c83485e24f2e6c3</citedby><cites>FETCH-LOGICAL-c440t-7f5d64a11ba3d7c766828961cea3fa9b535232de44d772516c83485e24f2e6c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2759702395?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36460533$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanaka, Hidenori</creatorcontrib><creatorcontrib>Mukai, Junji</creatorcontrib><creatorcontrib>Kushibiki, Kenichi</creatorcontrib><creatorcontrib>Mizushima, Sayuri</creatorcontrib><creatorcontrib>Maeda, Kyoko</creatorcontrib><creatorcontrib>Fujimoto, Yuko</creatorcontrib><creatorcontrib>Sawada, Ryugo</creatorcontrib><creatorcontrib>Oda, Manabu</creatorcontrib><creatorcontrib>Okuda, Hiroshi</creatorcontrib><creatorcontrib>Yamaki, Mayumi</creatorcontrib><creatorcontrib>Hashiguchi, Shin</creatorcontrib><creatorcontrib>Kawai, Ichiro</creatorcontrib><creatorcontrib>Kawaguchi, Izumi</creatorcontrib><creatorcontrib>Masuda, Noriyuki</creatorcontrib><creatorcontrib>Matsushita, Haruhiko</creatorcontrib><title>Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•Anti-SP antibody titer compared after second and third doses of the BNT162b2 vaccine.•Study conducted on healthcare workers directly exposed to COVID-19 patients.•Anti-SP IgG titer decreased slowly after second dose of the vaccine.•Peak IgG titer 4.1-fold higher after the third dose than after first and second doses.•Adverse events following immunization were generally mild to moderate.
Administration of three doses of Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine was completed in Japan in the spring of 2022. This study aimed to evaluate the antibody responses, and kinetics of three doses of vaccine in healthcare workers (HCWs).
We conducted a longitudinal cohort study with HCWs, who had no history of COVID-19 or serologic evidence of SARS-CoV-2 infection, from a single hospital. Immunoglobulin G (IgG) titers of anti-SARS-CoV-2 spike protein (SP) and nucleocapsid protein (NP) titers were measured using an automated chemiluminescent enzyme immunoassay system.
A total of 636 HCWs participated in the study. The anti-SP IgG titers decreased slowly after the second dose of the BNT162b2 vaccine in all participants, and robust antibody response was observed after the third dose of the vaccine. The peak anti-SP IgG titer after the third dose was approximately 4.1-fold higher than that after the first and second doses, and the rate of decrease in the anti-SP IgG titer after the third dose was significantly more gradual, than that after the second dose. After the second dose of vaccine, the antibody response was weaker in older participants than in younger participants, and in males than in females respectively, whereas the response to the third dose of vaccine did not differ significantly by sex or age. Adverse events following immunization were generally mild to moderate.
The third dose of the BNT162b2 vaccine induced a significant and sustained increase in anti-SP IgG titers, and was generally safe and well-tolerated.</description><subject>Age</subject><subject>Aged</subject><subject>Antibodies</subject><subject>Antibodies, Viral</subject><subject>Antibody Formation</subject><subject>Antibody response</subject><subject>BNT162 Vaccine</subject><subject>BNT162b2 vaccine</subject><subject>Booster vaccination</subject><subject>Chemiluminescence</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Enzyme immunoassay</subject><subject>Female</subject><subject>Health care</subject><subject>Health Personnel</subject><subject>Healthcare workers</subject><subject>Humans</subject><subject>IgG antibody</subject><subject>Immunization</subject><subject>Immunoassay</subject><subject>Immunoglobulin G</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Males</subject><subject>Medical personnel</subject><subject>mRNA</subject><subject>mRNA Vaccines</subject><subject>Nucleocapsids</subject><subject>Pandemics</subject><subject>Proteins</subject><subject>Questionnaires</subject><subject>SARS-CoV-2</subject><subject>SARS-CoV-2 spike protein</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Sex differences</subject><subject>Spike protein</subject><subject>Vaccines</subject><subject>Values</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU1vEzEQQC0EoqHwE0CWuHDx1l9r755QCIVWqlqpjSpulteeVRw262JvgvrvcUjaAxcOlj3Wmxl7HkLvGa0YZepsXe2sc2GEilPOK8YqKtsXaMYaLQivWfMSzShXkkhGf5ygNzmvKaW1YO1rdCKUVOUsZiif9z24CcceTysoKySPfcywv_lyvWSKdxwvbu4vvxLW4s3t9RwfG-M4YjtOgdzNb-_IIt4T_jfuon_EA-xgyDiMeAV2mFbOJsC_Y_oJKb9Fr3o7ZHh33E_R8tv5cnFBrm6-Xy7mV8RJSSei-9oraRnrrPDaaaUa3rSKObCit21Xi5oL7kFKr3X5sXKNkE0NXPYclBOn6NOh7EOKv7aQJ7MJ2cEw2BHiNhuupRJNI7Qu6Md_0HXcprE8rlB1qykXbV2o-kC5FHNO0JuHFDY2PRpGzV6KWZvjbMxeimHMFCkl78Ox-rbbgH_OerJQgM8HoIwMdgGSyS7A6MCHVOQYH8N_WvwBs6CcLg</recordid><startdate>20230109</startdate><enddate>20230109</enddate><creator>Tanaka, Hidenori</creator><creator>Mukai, Junji</creator><creator>Kushibiki, Kenichi</creator><creator>Mizushima, Sayuri</creator><creator>Maeda, Kyoko</creator><creator>Fujimoto, Yuko</creator><creator>Sawada, Ryugo</creator><creator>Oda, Manabu</creator><creator>Okuda, Hiroshi</creator><creator>Yamaki, Mayumi</creator><creator>Hashiguchi, Shin</creator><creator>Kawai, Ichiro</creator><creator>Kawaguchi, Izumi</creator><creator>Masuda, Noriyuki</creator><creator>Matsushita, Haruhiko</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20230109</creationdate><title>Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers</title><author>Tanaka, Hidenori ; Mukai, Junji ; Kushibiki, Kenichi ; Mizushima, Sayuri ; Maeda, Kyoko ; Fujimoto, Yuko ; Sawada, Ryugo ; Oda, Manabu ; Okuda, Hiroshi ; Yamaki, Mayumi ; Hashiguchi, Shin ; Kawai, Ichiro ; Kawaguchi, Izumi ; Masuda, Noriyuki ; Matsushita, Haruhiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-7f5d64a11ba3d7c766828961cea3fa9b535232de44d772516c83485e24f2e6c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age</topic><topic>Aged</topic><topic>Antibodies</topic><topic>Antibodies, Viral</topic><topic>Antibody Formation</topic><topic>Antibody response</topic><topic>BNT162 Vaccine</topic><topic>BNT162b2 vaccine</topic><topic>Booster vaccination</topic><topic>Chemiluminescence</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Enzyme immunoassay</topic><topic>Female</topic><topic>Health care</topic><topic>Health Personnel</topic><topic>Healthcare workers</topic><topic>Humans</topic><topic>IgG antibody</topic><topic>Immunization</topic><topic>Immunoassay</topic><topic>Immunoglobulin G</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Males</topic><topic>Medical personnel</topic><topic>mRNA</topic><topic>mRNA Vaccines</topic><topic>Nucleocapsids</topic><topic>Pandemics</topic><topic>Proteins</topic><topic>Questionnaires</topic><topic>SARS-CoV-2</topic><topic>SARS-CoV-2 spike protein</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Sex differences</topic><topic>Spike protein</topic><topic>Vaccines</topic><topic>Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanaka, Hidenori</creatorcontrib><creatorcontrib>Mukai, Junji</creatorcontrib><creatorcontrib>Kushibiki, Kenichi</creatorcontrib><creatorcontrib>Mizushima, Sayuri</creatorcontrib><creatorcontrib>Maeda, Kyoko</creatorcontrib><creatorcontrib>Fujimoto, Yuko</creatorcontrib><creatorcontrib>Sawada, Ryugo</creatorcontrib><creatorcontrib>Oda, Manabu</creatorcontrib><creatorcontrib>Okuda, Hiroshi</creatorcontrib><creatorcontrib>Yamaki, Mayumi</creatorcontrib><creatorcontrib>Hashiguchi, Shin</creatorcontrib><creatorcontrib>Kawai, Ichiro</creatorcontrib><creatorcontrib>Kawaguchi, Izumi</creatorcontrib><creatorcontrib>Masuda, Noriyuki</creatorcontrib><creatorcontrib>Matsushita, Haruhiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanaka, Hidenori</au><au>Mukai, Junji</au><au>Kushibiki, Kenichi</au><au>Mizushima, Sayuri</au><au>Maeda, Kyoko</au><au>Fujimoto, Yuko</au><au>Sawada, Ryugo</au><au>Oda, Manabu</au><au>Okuda, Hiroshi</au><au>Yamaki, Mayumi</au><au>Hashiguchi, Shin</au><au>Kawai, Ichiro</au><au>Kawaguchi, Izumi</au><au>Masuda, Noriyuki</au><au>Matsushita, Haruhiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2023-01-09</date><risdate>2023</risdate><volume>41</volume><issue>2</issue><spage>365</spage><epage>371</epage><pages>365-371</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•Anti-SP antibody titer compared after second and third doses of the BNT162b2 vaccine.•Study conducted on healthcare workers directly exposed to COVID-19 patients.•Anti-SP IgG titer decreased slowly after second dose of the vaccine.•Peak IgG titer 4.1-fold higher after the third dose than after first and second doses.•Adverse events following immunization were generally mild to moderate.
Administration of three doses of Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine was completed in Japan in the spring of 2022. This study aimed to evaluate the antibody responses, and kinetics of three doses of vaccine in healthcare workers (HCWs).
We conducted a longitudinal cohort study with HCWs, who had no history of COVID-19 or serologic evidence of SARS-CoV-2 infection, from a single hospital. Immunoglobulin G (IgG) titers of anti-SARS-CoV-2 spike protein (SP) and nucleocapsid protein (NP) titers were measured using an automated chemiluminescent enzyme immunoassay system.
A total of 636 HCWs participated in the study. The anti-SP IgG titers decreased slowly after the second dose of the BNT162b2 vaccine in all participants, and robust antibody response was observed after the third dose of the vaccine. The peak anti-SP IgG titer after the third dose was approximately 4.1-fold higher than that after the first and second doses, and the rate of decrease in the anti-SP IgG titer after the third dose was significantly more gradual, than that after the second dose. After the second dose of vaccine, the antibody response was weaker in older participants than in younger participants, and in males than in females respectively, whereas the response to the third dose of vaccine did not differ significantly by sex or age. Adverse events following immunization were generally mild to moderate.
The third dose of the BNT162b2 vaccine induced a significant and sustained increase in anti-SP IgG titers, and was generally safe and well-tolerated.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>36460533</pmid><doi>10.1016/j.vaccine.2022.11.049</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2023-01, Vol.41 (2), p.365-371 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2746388377 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Age Aged Antibodies Antibodies, Viral Antibody Formation Antibody response BNT162 Vaccine BNT162b2 vaccine Booster vaccination Chemiluminescence Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Enzyme immunoassay Female Health care Health Personnel Healthcare workers Humans IgG antibody Immunization Immunoassay Immunoglobulin G Longitudinal Studies Male Males Medical personnel mRNA mRNA Vaccines Nucleocapsids Pandemics Proteins Questionnaires SARS-CoV-2 SARS-CoV-2 spike protein Severe acute respiratory syndrome coronavirus 2 Sex differences Spike protein Vaccines Values |
| title | Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T05%3A05%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20the%20third%20dose%20of%20BNT162b2%20COVID-19%20mRNA%20vaccine%20on%20anti-SARS-CoV-2%20antibody%20levels%20in%20healthcare%20workers&rft.jtitle=Vaccine&rft.au=Tanaka,%20Hidenori&rft.date=2023-01-09&rft.volume=41&rft.issue=2&rft.spage=365&rft.epage=371&rft.pages=365-371&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2022.11.049&rft_dat=%3Cproquest_cross%3E2746388377%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2759702395&rft_id=info:pmid/36460533&rft_els_id=S0264410X22014621&rfr_iscdi=true |